【摘要】 波替单抗(万珂)是第一个进入临床试验的蛋白酶体抑制剂。美国FDA和欧盟EMEA已批准用于治疗复发或难治性多发性骨髓瘤(MM)。继续进行中的试验用波替单抗作为一线治疗MM结果令人鼓舞。套细胞淋巴瘤(MCL)是一种攻击性的B-细胞霍奇金淋巴瘤,缺乏最佳治疗选择,临床结果证实波替单抗治疗复发或难治性MCL有效,且有预期和可处理的毒性。波替单抗合并常规药物治疗血液恶性肿瘤和有些实体瘤,如非小细胞肺癌、雄激素非依赖性前列腺癌,证明有化学增敏作用。单用波替单抗或与其他抗肿瘤联合治疗恶性肿瘤值得进一步研究。更多还原

【Abstract】 Bortezonib (velcade) is the first proteasome inhibitor that has entered clinical trial.Both the FDA (US) and EMEA (Eur) granted an approval for the use of bortezomib for the treatment of re- lapsed or refractory multiple myeloma (MM).Results of ongoing trial with bortezomib in the first-line treatment of MM have been extremely encouraging.Mantle cell lymphoma (MCL) is an aggressive form of B-cell non-Hodgkin’s lymphoma and lack of better therapeutic options.Clinical results confirm the ac- tivity of bortezomib in relapsed or refractory MCL,with predictable and manageable toxicities.Clinical tri- als have demonstrated a chemo-sensitizing effect of bortezmoib on conventional agents in hematological malignancies and some solid tumors such as NSCLC and androgen-independent prostate.Further studies with bortezomib as monotherapy and combination regimens in the treatment of hematologic and solid malig- nancies are warranted.更多还原